HCC Response Assessment by MRI After SBRT
March 17, 2017 updated by: Institut de Cancérologie de Lorraine
Tumor Response Assessment by MRI Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
The aim of this work was to describe SBRT different presentations, to study predictive factors for tumor responses following treatment, and to compare tumor response assessments according to the Response Evaluation Criteria
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
35
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients records were extracted from the electronic health record system of Institut de Cancérologie de Lorraine
Description
- Inclusion Criteria: the standard criteria for treating HCC patients with SBRT : an Eastern Cooperative Oncology Group (ECOG) score of 2, inoperable tumors (e.g. the patient being unfit for surgery, or tumor-related contraindications), and a maximum tumor diameter of 6 cm. The HCC diagnosis could be histological or based on the radiological criteria of the American Association for the Study of Liver Diseases (AASLD)
- Exclusion Criteria:no follow-up by MR imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor response assessments
Time Frame: Within the 24 months after SBRT
|
The tumor response was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
Within the 24 months after SBRT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2011
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
February 1, 2015
Study Registration Dates
First Submitted
March 16, 2017
First Submitted That Met QC Criteria
March 17, 2017
First Posted (Actual)
March 23, 2017
Study Record Updates
Last Update Posted (Actual)
March 23, 2017
Last Update Submitted That Met QC Criteria
March 17, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013_ICL_0001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.